Latest New England Journal Stories
Automated Security Alert’s Medical Alarms Can Add Years to Life at Home Pittsburgh, PA (PRWEB) July 03, 2013 “According to the New England Journal
Results of a Phase III clinical trial showed that a simple drug regimen of two anti-clotting drugs – clopidogrel and aspirin – lowered the risk of stroke by almost one-third, compared to the standard therapy of aspirin alone, when given to patients who had minor or transient stroke symptoms to prevent subsequent attacks.
One of the largest clinical trials done in infants with congenital (present at birth) heart diseases.
In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).
Two clinical studies published in the New England Journal of Medicine with an accompanying editorial suggest that the novel agent ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chronic lymphocytic leukemia (CLL) and for patients with mantle cell lymphoma (MCL).
Although as many as 25 percent of patients undergoing surgery suffer from sleep apnea, few hospitals have policies to help manage the risks of this condition during surgery, and there is little evidence to help guide anesthesiologists and surgeons caring for these patients.
Harvard Stem Cell Institute (HSCI) researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.
Uterine leiomyomata, or fibroids, are benign tumors that nevertheless affect the health of millions of women.
Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.
A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for this deadly lung disease.